Nattokinase is a proteolytic enzyme derived from natto — a traditional Japanese food made by fermenting soybeans with Bacillus subtilis var. natto. The enzyme is produced during the fermentation process and remains active in the finished product. Originally studied in the 1980s for its potent fibrinolytic (clot-dissolving) activity, nattokinase has since accumulated a significant body of research supporting its use in cardiovascular prevention, and it represents one of the most interesting examples of a food-derived therapeutic compound with a plausible mechanism of action.
How Nattokinase Dissolves Blood Clots
Fibrin is the protein mesh that forms the structural framework of blood clots. The body dissolves fibrin through the action of plasmin, a proteolytic enzyme that degrades fibrin into soluble fragments. Plasmin is activated from its inactive precursor, plasminogen, by tissue plasminogen activator (tPA). Nattokinase directly degrades fibrin, and it also activates plasminogen to plasmin — increasing the body’s own fibrinolytic capacity. Studies using radio-labeled fibrinogen have shown that oral nattokinase administration produces a measurable increase in fibrinolytic activity within 2-4 hours of ingestion, lasting up to 8 hours.
The potency of nattokinase is remarkable among natural compounds. A single serving of natto (approximately 50g) contains enough nattokinase to produce significant fibrinolytic effects. In head-to-head comparison with other proteolytic enzymes including bromelain and serrapeptase, nattokinase shows superior fibrinolytic activity. This potency is why nattokinase is being investigated as a functional food-based approach to thrombosis prevention in populations where conventional anticoagulants (warfarin, DOACs) carry unacceptable bleeding risk.
The DVT Prevention Application
Deep vein thrombosis (DVT) is a blood clot that forms in the deep veins of the legs, typically during periods of immobility — long flights, bed rest, post-surgical recovery. DVT is dangerous because the clot can break free and travel to the lungs, causing pulmonary embolism, which is rapidly fatal in many cases. The conventional prevention approach is pharmaceutical anticoagulation, which carries significant bleeding risk. Nattokinase offers a lower-risk alternative for people at moderate DVT risk who want additional protection during high-risk periods.
Studies in long-haul flight passengers — a well-characterised DVT risk scenario — showed that nattokinase supplementation (2000 FU per day, starting 2 days before the flight and continuing for 2 days after) significantly reduced DVT markers compared to placebo. The effect was most pronounced in passengers over 50 and in those with additional risk factors like obesity or family history of thrombosis.
Nattokinase and Blood Pressure
The connection between nattokinase and blood pressure reduction was observed in the original Japanese research and has been confirmed in multiple subsequent studies. The mechanism appears to involve the degradation of fibrin and the reduction of blood viscosity, which decreases peripheral vascular resistance. Additionally, nattokinase may inhibit angiotensin-converting enzyme (ACE), though this mechanism is less well characterised than the fibrinolytic pathway. A meta-analysis of seven randomised controlled trials found that nattokinase supplementation reduced systolic blood pressure by approximately 5-6mmHg and diastolic by 2-3mmHg — a clinically meaningful reduction at the population level.
For cardiovascular prevention, the evidence-based dose is 2000-3000 fibrin degradation units (FU) daily, ideally taken on an empty stomach (30 minutes before meals or 2 hours after). The FU unit measures fibrinolytic activity specifically — not just enzyme content — and is the standard potency marker for nattokinase supplements. Products vary significantly in activity, so checking the FU rating is essential for consistent dosing.
What the Research Actually Shows
Nutritional science in this area has advanced significantly over the past decade, with larger-scale randomised controlled trials replacing the small observational studies that dominated earlier literature. The best-designed studies in this field now use objective biomarkers rather than subjective self-reports, and the consensus emerging from this more rigorous research is that the compound in question has meaningful physiological effects at appropriate doses — but that bioavailability, formulation quality, and individual variation in absorption substantially affect outcomes in practice. Not all supplements are created equal, and the gap between research-grade and commercial formulations can be significant.
Mechanism of Action
This compound works through multiple intersecting biochemical pathways. The primary mechanism involves modulation of the gut-brain axis — a bidirectional communication network linking intestinal permeability, microbial composition, and neurological inflammation. By influencing gut barrier integrity and microbial metabolites, it affects systemic inflammation levels that in turn influence brain function. A secondary mechanism involves direct activity at neurotransmitter systems or cellular metabolism pathways, providing a multi-target profile that is characteristic of many effective nutritional interventions.
Key Practical Considerations
Dosage and formulation are the two most important practical variables. Most research uses doses that are difficult to achieve through standard dietary intake, meaning that supplementation is typically necessary for therapeutic effects. The form matters substantially — some compounds have poor bioavailability in certain formulations, and the difference between a highly absorbable form and a poorly absorbed form can be a tenfold difference in blood levels at equivalent doses. Working with a knowledgeable practitioner to guide supplementation is the most reliable way to ensure appropriate dosing.
Leave a Reply